Is Crop Life Scienc overvalued or undervalued?

As of 17 October 2025, the valuation grade for Crop Life Science has moved from fair to expensive, indicating that the company is currently overvalued. Key ratios include a PE Ratio of 14.50, an EV to EBITDA of 8.38, and a ROE of 8.47%. In comparison to peers, UPL is rated attractive with a PE of 37.91, while Bayer CropScience is also expensive with a PE of 38.24, highlighting that Crop Life Science's valuation is not competitive within the industry.
Given these metrics and the peer comparison, Crop Life Science appears to be overvalued. The company's recent stock performance shows a year-to-date return of 11.67%, outperforming the Sensex's 8.73%, but this does not sufficiently justify the expensive valuation relative to its peers.